Pediatric inflammatory multisystem syndrome associated with COVID-19: a clinical case

Background. In October 30, 2020, National Institute for Health and Care Excellence (NICE) defined post-COVID syndrome as a set of complaints and symptoms that develop during or after COVID-19, persist for more than 12 weeks, and are not explained by an alternative diagnosis, with the most severe being development of pediatric inflammatory multisystem syndrome in children (PIMS). Description of the clinical case. This article presents a clinical case of the development of PIMS in a 7-year-old patient with an analysis of the dynamics of the clinical picture in the focus of laboratory and instrumental methods of examination and ongoing therapy. The presented case demonstrates the development of PIMS with a favorable outcome in the form of recovery. At the same time, all the main typical manifestations are defined. This case clearly demonstrates that PIMS can develop in children even after an asymptomatic form of the disease. The uniqueness of this case lies in the fact that due to the development of sepsis and the impossibility of using genetically engineered drugs, positive dynamics with the subsequent recovery of the child was achieved by the use of combination of anticoagulants, antibacterial drugs and systemic glucocorticosteroids with constant dose adjustment depending on changes in laboratory parameters. Conclusion. Demonstration of clinical cases of PIMS in children is important and relevant information for practitioners and researchers. Further research to develop rehabilitation programs and treatment methods to minimize delayed complications of coronavirus infection in childhood is required.

COVID-19, children, COVID-19, post-COVID syndrome, multisystem inflammatory syndrome in children, coronavirus infection